anti-cancer biosimilar
Scope
Date
~
-
Bio & Pharma
Volpara to supply breast cancer SW to US Defense Health Agency
Lunit, a South Korean cancer diagnostics AI company, said on Monday its US subsidiary Volpara Health secured a 10 billion won ($7.5 million) contr...
Nov 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Steqeyma in Europe
South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...
Nov 05, 2024 (Gmt+09:00)
-
Energy
Czech anti-trust body puts signing of nuclear power deal on hold
The Czech anti-trust body put a temporary block on the conclusion of a contract with Korea Hydro & Nuclear Power Co. (KHNP) for the construction...
Oct 31, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis eyes record sales in 2024 after stellar Q3
Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, is expected to post its best-ever annual revenue this year after sal...
Oct 24, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Oct 11, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply breast, stomach cancer treatment to Brazil
Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...
Sep 13, 2024 (Gmt+09:00)
-
Business & Politics
South Korea scraps anti-nuclear policy with approval of two nuclear plants
South Korea has approved the construction of two nuclear power plants, officially ending its anti-nuclear policy pursued by the previous Moon Jae-in...
Sep 13, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion earmarks billions of dollars to build CDMO plant: chairman
Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...
Sep 11, 2024 (Gmt+09:00)
-
Human Interest
After 37 years of use, Kim returns trusty microwave to Samsung with love
For 37 years, a simple microwave made by Samsung Electronics Co. sat in the kitchen of Kim Kyu-won, providing much more than convenience.It was ther...
Sep 11, 2024 (Gmt+09:00)
-
Bio & Pharma
SK Group’s 3rd-generation daughter comes to the fore
Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut during an SK Biopharmaceuticals Co. video confer...
Aug 30, 2024 (Gmt+09:00)
-
Bio & Pharma
Gencurix, Hitachi to cooperate on molecular diagnostics
South Korean biotech company Gencurix Inc. said on Tuesday that it will cooperate with Japan's Hitachi High-Tech Corporation to enter the Japanese c...
Aug 29, 2024 (Gmt+09:00)
-
Chemical Industry
Samhwa Paint launches anti-rust product Knok-Stop
South Korea's Samhwa Paint Industrial said on Wednesday that it has introduced a new water-based primer, Knok-Stop, designed to convert rust on meta...
Aug 22, 2024 (Gmt+09:00)
-
Bio & Pharma
Volpara to supply cancer diagnostics SW to Intermountain Health
Lunit, a South Korean cancer diagnostics AI company, announced on Wednesday that its subsidiary Volpara Health, a New Zealand-based AI software deve...
Aug 21, 2024 (Gmt+09:00)
-
Bio & Pharma
Yuhan’s lung cancer drug clears FDA hurdle for global debut
A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...
Aug 21, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Zymfentra joins US insurance-covered drug lists
South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...
Aug 06, 2024 (Gmt+09:00)
-
Regulations
S.Korea, China's technology leak, anti-dumping disputes surge
South Korean companies are getting tough on anti-dumping and patent infringement cases as they feel threatened by the intensifying price competition...
Aug 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets approval of Steqeyma in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...
Jul 31, 2024 (Gmt+09:00)
-
Bio & Pharma
Lunit to supply AI cancer diagnostics to Qatar
Lunit Inc., a South Korean cancer diagnostics AI company, announced on Monday that it will provide its AI breast cancer screening solution Lunit Ins...
Jul 22, 2024 (Gmt+09:00)
-
ESG
LG Energy Solution acquires anti-bribery certification
South Korea's LG Energy Solution Ltd. announced on Thursday that it achieved ISO 37001 certification, an international standard for anti-bribery man...
Jul 11, 2024 (Gmt+09:00)
-
Artificial intelligence
Lunit eyes developing markets with AI cancer diagnostics
Lunit Inc., a South Korean cancer diagnostics AI company, will accelerate its inroads into developing markets grappling with inadequate cancer diagn...
Jul 09, 2024 (Gmt+09:00)
-
Bio & Pharma
JLK gets FDA OK for prostate cancer diagnosis AI solution
South Korea’s JLK Inc., an AI-based diagnosis solution and platform maker, announced on Monday that it got approval from the US Food and Drug ...
Jun 25, 2024 (Gmt+09:00)
-
Chemical Industry
Lotte Chemical develops anti-thermal runaway material
Lotte Chemical Corp., South Korea’s second-largest petrochemicals company seeking to ramp up value-added advanced materials production, has de...
Jun 20, 2024 (Gmt+09:00)
-
E-commerce
Coupang fined $102 mn for alleged search algorithm manipulation
Coupang Inc., South Korea’s largest e-commerce platform, was fined 140 billion won ($102 million) on Thursday for allegedly manipulating searc...
Jun 13, 2024 (Gmt+09:00)
-
Bio & Pharma
Korean biotech Bertis to join BIO 2024 for global reach
South Korean biotech Bertis Inc. will deliver presentations at the BIO International Convention, one of the world’s largest bio and healthcare...
May 29, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis leads in Soliris biosimilar market in Europe
STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Soliris for the treatment of patients with rare, life-threatening disease paroxysmal nocturnal...
May 27, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
May 23, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Lunit buys breast cancer detection AI firm Volpara Health
Lunit Inc., a South Korean cancer diagnostics AI company, has completed the acquisition of Volpara Health Technologies Ltd., a New Zealand-based AI ...
May 22, 2024 (Gmt+09:00)
-
Bio & Pharma
Investors dump Korean biotech HLB stocks on FDA rejection
HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...
May 17, 2024 (Gmt+09:00)
-
Bio & Pharma
S.Korean anti-obesity drugmakers eye niche demand
The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...
May 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
Latest News
- 1 Lee Jae-myung to meet with top business leaders this week ahead of G7 summit
- 2 Korea to allow non-profits to buy bad consumer loans
- 3 LG to drive future growth in emerging markets with battery prowess
- 4 South Korean President Lee, Japanese Prime Minister Ishiba seek closer ties
- 5 Naver Ventures to plant flag in Silicon Valley with TwelveLabs bet